Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Xenon Clear all
Completed Early Phase 1 Interventional

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

NCT02826343
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

Pulmonary Hypertension SOLAR

NCT04778046
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration

NCT02316379
View directory record Official record
Conditions
Respiratory Disorders
Interventions
Hyperpolarized 129 Xenon, MRI
Drug · Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

129 Xenon Imaging in Patients Treated With Sotatercept

NCT06351345
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Withdrawn Phase 2 Interventional

Trial of Low-Dose Xenon For The Treatment Of Obsessive-Compulsive Disorder

NCT02098148
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Xenon, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
Mario Castro, MD, MPH
Other
Eligibility
3 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Not applicable Interventional Results available

Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection

NCT03349268
View directory record Official record
Conditions
Healthcare Associated Infection, Clostridium Difficile Infection, Infection Due to Multidrug Resistant Bacteria
Interventions
Pulsed xenon ultraviolet (PX-UV) Device, Sham Device
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
25,732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 5, 2026, 1:37 PM EDT
Terminated Phase 1 Interventional

Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI

NCT05433961
View directory record Official record
Conditions
COPD
Interventions
MagniXene Hyperpolarized Xenon MRI
Drug
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients

NCT01419275
View directory record Official record
Conditions
Cerebrovascular Accident, Moyamoya Disease
Interventions
Xenon contrast agent, Magnetic Resonance Imaging
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 5, 2026, 1:37 PM EDT
Not yet recruiting Phase 3 Interventional

Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

NCT03176186
View directory record Official record
Conditions
Post-Cardiac Arrest Syndrome
Interventions
Xenon
Combination Product
Lead sponsor
Invero Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Hartford, Connecticut • Gainesville, Florida • Gulfport, Mississippi + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

NCT06104228
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

NCT06012500
View directory record Official record
Conditions
ILD
Interventions
Xenon-129
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Active, not recruiting Early Phase 1 Interventional

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

NCT03748446
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Depression
Interventions
Xenon, Nitrogen gas
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Phase 3 Interventional

Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Transplant

NCT03418090
View directory record Official record
Conditions
Pulmonary Surgical Procedures
Interventions
129Xe MRI, 133XE scintigraphy
Drug
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Patients With and Without Phonotrauma

NCT05625191
View directory record Official record
Conditions
Phonotrauma
Interventions
Acoustic voice analysis, High-speed videoendoscopy
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

NCT06856525
View directory record Official record
Conditions
Electronic Cigarette Related Lung Damage
Interventions
Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test, Chest CT
Drug · Diagnostic Test
Lead sponsor
Y. Michael Shim, MD
Other
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

NCT02478268
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized 129-Xenon gas, MRI
Drug · Device
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 5, 2026, 1:37 PM EDT
Terminated Phase 3 Interventional Results available

A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy

NCT03054870
View directory record Official record
Conditions
Lung Structure Determination
Interventions
Xe-133, Technegas
Drug
Lead sponsor
Cyclomedica Australia PTY Limited
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Clearwater, Florida • Jacksonville, Florida • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Sep 5, 2026, 1:37 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Functional Applications of Hyperpolarized 129Xe MRI

NCT01697332
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Hyperpolarized 129Xe gas
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Not applicable Interventional Results available

Fluorescent Cholangiography vs White Light for Bile Ducts Identification

NCT02702843
View directory record Official record
Conditions
Cholecystitis, Cholelithiasis
Interventions
Laparoscopic cholecystectomy with Xenon light, Laparoscopic cholecystectomy (fluorescent cholangiography)
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Phase 2 Interventional Results available

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

NCT04071769
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

129Xe MRI Cardiopulmonary

NCT06038630
View directory record Official record
Conditions
Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia, Polycythemia, Dyspnea
Interventions
Hyperpolarized Xe129, Oxygen Administration
Drug · Other
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

Using Xe MRI to Guide Radiation Therapy for Lung Cancer

NCT06925295
View directory record Official record
Conditions
Imaging Techniques
Interventions
Xenon MRI, Pulmonary Function Testing, Quality of Life Questionnaire, Medical Research Council Dyspnea score, St. George's Respiratory Questionnaire, Blood Biomarkers
Drug · Diagnostic Test · Other
Lead sponsor
Sean Fain
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Terminated Phase 3 Interventional Results available

Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism

NCT01458639
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Technegas V SPECT imaging, Xenon-133 Ventilation Planar imaging
Drug
Lead sponsor
Cyclomedica Australia PTY Limited
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Sep 5, 2026, 1:37 PM EDT